Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 13, Issue 5, Pages 848-854Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.2c00120
Keywords
Chromatin; Drug discovery; Epigenetics; Histone; Nucleosome
Categories
Funding
- RIKEN Program for Drug Discovery and Medical Technology Platforms
- Japan Society for the Promotion of Science [20H03388, 20K21406]
- Japan Agency for Medical Research and Development (AMED) [JP21am0101113]
- AMED Drug Discovery Informatics project
- Grants-in-Aid for Scientific Research [20K21406, 20H03388] Funding Source: KAKEN
Ask authors/readers for more resources
A series of S2157 derivatives were designed, synthesized, and evaluated, with compound 10 showing the most desirable activities and its eutomer S1427 being successfully isolated. S1427 exhibited potent LSD1 inhibitory activity, as well as desirable hERG channel inhibition and microsomal stability.
Lysine-specific demethylase 1 (LSD1/KDM1A) is a promising therapeutic target for the treatment of cancers. Several derivatives of tranylcypromine (trans-2-phenylcyclopropylamine) have been developed as LSD1 inhibitors. One such derivative is S2157; however, this compound has a high hERG channel inhibitory activity and a low microsomal stability, making it unsuitable as a drug candidate. Here, using an in silk() hERG inhibition prediction model, we designed, synthesized, and evaluated a novel series of S2157 derivatives characterized by modifications of the benzyloxy and piperazine groups. Among the synthesized derivatives, a compound possessing 2-fluoropyridine and 2,8-diaza-spiro[4.5]decane groups (compound 10) showed the most desirable activities, and its eutomer, S1427, was isolated by the optical resolution of 10. In addition to potent LSD1 inhibitory activity, S1427 exhibited desirable hERG channel inhibition and microsomal stability profiles.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available